S. Hall

发表

The effect of hormone replacement therapy on CYP3A activity

S. Wrighton, J. Gorski, Zaiqi Wang, 2000, Clinical pharmacology and therapeutics.

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin

J. Gorski, B. Haehner‐Daniels, S. Hall, 1998, Clinical pharmacology and therapeutics.

Furosemide absorption in patients with cirrhosis

S. Hall, M. Fredrick, D. Pound, 1991, Clinical pharmacology and therapeutics.

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia

S. Hall, K. McCammack, Akinbode Egbelakin, 2011, Pediatric blood & cancer.

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

David A. Flockhart, Zeruesenay Desta, Stephen D. Hall, 2003, Journal of Pharmacology and Experimental Therapeutics.

Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window

P. Kulanthaivel, S. Hall, S. Wijayawardana, 2015, Clinical pharmacology and therapeutics.

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach

Leon Aarons, Nikolaos Tsamandouras, Aleksandra Galetin, 2014, Pharmaceutical Research.

The interaction of diltiazem with simvastatin

S. Hall, D. Brater, Omaima Mousa, 2000, Clinical pharmacology and therapeutics.

The effect of rifampin administration on the disposition of fexofenadine

B. Haehner‐Daniels, S. Hall, M. Hamman, 2001, Clinical pharmacology and therapeutics.

Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin.

J. Gorski, B. Haehner‐Daniels, S. Hall, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling

M. Posada, P. Kulanthaivel, S. Hall, 2020, Journal of clinical pharmacology.

Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling

Maria M. Posada, Stephen D. Hall, K. Hillgren, 2015, Drug Metabolism and Disposition.

The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis

D. Jones, T. Tracy, S. Hall, 1992, European Journal of Clinical Pharmacology.

Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5)

Sean Ekins, Lang Li, S. Ekins, 2007, Drug Metabolism and Disposition.

Variable Furosemide Absorption and Poor Predictability of Response in Elderly Patients

M. Murray, S. Hall, D. Brater, 1997, Pharmacotherapy.

Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by Ketoconazole

J. Chien, J. Mao, S. Hall, 2013, Drug Metabolism and Disposition.

Disease–Drug Interactions in Inflammatory States via Effects on CYP‐Mediated Drug Clearance

S. Hall, D. Coutant, S. Hall, 2018, Journal of clinical pharmacology.

Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes.

B. Ring, S. Wrighton, S. Hall, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Special Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems CYP 2 B 6 Pharmacogenetics – Based In Vitro – In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling s

Lang Li, S. Hall, Z. Desta, 2013 .

CYP2B6 Pharmacogenetics–Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling

Lang Li, S. Hall, Z. Desta, 2013, Drug Metabolism and Disposition.

Impaired hepatic elimination of paranitrophenol and its metabolites in the rat following chronic ethanol pretreatment.

R. Branch, S. Hall, S. Schenker, 1989, Alcoholism, clinical and experimental research.

Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co‐regulated substrate, mephobarbital

R. Branch, S. Hall, G. Wilkinson, 1986, Clinical pharmacology and therapeutics.

Effect of Rosiglitazone on Serum Liver Biochemistries in Diabetic Patients with Normal and Elevated Baseline Liver Enzymes

N. Chalasani, S. Hall, E. Teal, 2005, The American Journal of Gastroenterology.

Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion

K. Hillgren, M. Posada, L. Tham, 2019, CPT: pharmacometrics & systems pharmacology.

Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.

N. Chalasani, S. Wrighton, S. Hall, 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: A comparison with nonalcoholics

N. Chalasani, J. Gorski, S. Hall, 2005, Hepatology.

BASED INACTIVATION OF CYTOCHROME P 450 3 A ( CYP 3 A ) BY HIV PROTEASE INHIBITORSa

C. Ernest, S. Hall, David R. Jones, 2004 .

Inhibition of Human Intestinal Wall Metabolism by Macrolide Antibiotics: Effect of Clarithromycin on Cytochrome P450 3A4/5 Activity and Expression

N. Chalasani, T. Skaar, J. Gorski, 2005, Clinical pharmacology and therapeutics.

Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.

N. Chalasani, S. Hall, M. Hamman, 2005, British journal of clinical pharmacology.

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N‐demethylation

D. Jones, J. Gorski, S. Hall, 1996, Clinical pharmacology and therapeutics.

Navajo neuropathy: Relation to MDR3 mRNA deficiency

V. Stanton, J. Gorski, S. Hall, 2002, Hepatology.

The effect of short‐ and long‐term administration of verapamil on the disposition of cytochrome P450 3A and P‐glycoprotein substrates

J. Gorski, Zaiqi Wang, S. Hall, 2006, Clinical pharmacology and therapeutics.

DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP 3 A 4 AND CYP 3 A 5 BY VERAPAMIL

S. Hall, David R. Jones, Ying-hong Wang, 2005 .

DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL

S. Hall, David R. Jones, Ying-hong Wang, 2005, Drug Metabolism and Disposition.

Mechanism-Based Inhibition of Human Cytochromes P450: In Vitro Kinetics and In Vitro—In Vivo Correlations

S. Hall, David R. Jones, S. Hall, 2001 .

Intravenous diltiazem and CYP3A-mediated metabolism.

D. Jones, S. Hall, D. Brater, 2000, British journal of clinical pharmacology.

Irreversible enzyme inhibition kinetics and drug-drug interactions.

M. Mohutsky, S. Hall, S. Hall, 2014, Methods in molecular biology.

Dose dependent inhibition of midazolam elimination by ketoconazole: Effect of CYP3A5 genotype

J. Chien, S. Hall, M. Hamman, 2005 .

The Effect of Echinacea (Echinacea purpurea Root) on Cytochrome P450 Activity in Vivo

Shiew-Mei Huang, J. Gorski, S. Hall, 2004, Clinical pharmacology and therapeutics.

Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.

L. Li, L. Pedersen, J. Goldstein, 1998, Archives of biochemistry and biophysics.

Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.

Cheng Cheng, R. Kim, E. Schuetz, 2012, Biochemical pharmacology.

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis

L. Szczech, S. Koletar, Samir K. Gupta, 2008, AIDS.

Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts

N. Chalasani, J. Gorski, S. Hall, 2001, Hepatology.

Association of genotypes of the CYP3A cluster with midazolam disposition in vivo

M. Radovich, S. Hall, S. Kim, 2009, The Pharmacogenomics Journal.

In vivo effect of clarithromycin on multiple cytochrome P450s.

J. Gorski, B. Haehner‐Daniels, S. Hall, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Hepatic Organic Anion Transporting Polypeptide–Mediated Clearance in the Beagle Dog: Assessing In Vitro–In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance

K. Hillgren, A. Galetin, J. Houston, 2018, Drug Metabolism and Disposition.

Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population‐Modeling Approach

L. Aarons, A. Galetin, A. Rostami-Hodjegan, 2014, Clinical pharmacology and therapeutics.

Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

M. Mohutsky, S. Hall, S. Hall, 2021, Methods in molecular biology.

The assessment of bioavailability in the presence of nonlinear elimination

S. Hall, G. Wilkinson, C. Mcallister, 1988, Journal of Pharmacokinetics and Biopharmaceutics.

Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population

L. Aarons, A. Galetin, S. Hall, 2017, Pharmacogenetics and genomics.

Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.

K. Tashima, L. Szczech, N. Franceschini, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination.

S. Hall, D. Brater, D. Rudy, 1999, British journal of clinical pharmacology.

Pharmacokinetic and Pharmacodynamic Alterations in the Roux-en-Y Gastric Bypass Recipients

N. Chalasani, S. Hall, R. Vuppalanchi, 2013, Annals of surgery.

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

Menggang Yu, B. Schneider, C. Sweeney, 2010, Cancer Chemotherapy and Pharmacology.

Pharmacogenomics of Gemcitabine Metabolism: Functional Analysis of Genetic Variants in Cytidine Deaminase and Deoxycytidine Kinase

B. Ring, S. Wrighton, Y. Qian, 2013, Drug Metabolism and Disposition.

Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.

L. Wienkers, S. Wrighton, W. Trager, 1994, Drug metabolism and disposition: the biological fate of chemicals.

Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition.

F. Guengerich, S. Hall, R. Knodell, 1987, The Journal of pharmacology and experimental therapeutics.

Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).

M. Mitchell, S. Hall, J. Witcher, 2015, Journal of pharmaceutical sciences.

Drug interactions with botanical products

Shiew-Mei Huang, S. Hall, Y. F. Lam, 2006 .

Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity.

D. Jones, J. Gorski, S. Hall, 1996, Journal of chromatography. B, Biomedical applications.

Mechanism-Based Inactivation of CYP 3 A by HIV Protease Inhibitors

C. Ernest, S. Hall, David R. Jones, 2005 .

COMPARATIVE METABOLIC CAPABILITIES OF CYP 3 A 4 , CYP 3 A 5 , AND CYP 3 A 7

B. Ring, S. Wrighton, S. Hall, 2002 .

DEXTROMETHORPHAN TO DEXTRORPHAN URINARY METABOLIC RATIO DOES NOT REFLECT DEXTROMETHORPHAN ORAL CLEARANCE

Lang Li, J. Gorski, S. Hall, 2005, Drug Metabolism and Disposition.

THE EFFECT OF ANESTHESIA AND SURGERY ON CYP3A ACTIVITY IN RATS

D. Beno, R. Kimura, S. Hall, 2004, Drug Metabolism and Disposition.

Association Between the CYP3A5 Genotype and Blood Pressure

N. Fineberg, D. O'Connor, Lang Li, 2005, Hypertension.

Association Between the CYP 3 A 5 Genotype and Blood Pressure

N. Fineberg, D. O'Connor, Lang Li, 2005 .

A Bayesian Meta-Analysis on Published Sample Mean and Variance Pharmacokinetic Data with Application to Drug–Drug Interaction Prediction

Menggang Yu, Lang Li, Lang Li, 2008, Journal of biopharmaceutical statistics.

Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches

S. Friedrich, S. Hall, A. Ke, 2015, Journal of clinical pharmacology.

Drug-induced QT Prolongation in Cirrhotic Patients With Transjugular Intrahepatic Portosystemic Shunt

N. Chalasani, J. Gorski, S. Hall, 2011, Journal of clinical gastroenterology.

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers

C. Fichtenbaum, A. Zolopa, J. Aberg, 2005, Clinical pharmacology and therapeutics.

Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines.

D. Foster, D. Murry, S. Hall, 2006, Biochemical pharmacology.

Efavirenz Clearance by PBPK Modeling

S. Hall, Z. Desta, S. Quinney, 2013 .

DMD051755 2004..2011

S. Hall, Z. Desta, S. Quinney, 2013 .

Determination of the epimeric composition of ibuprofenyl-CoA.

T. Tracy, S. Hall, S. Hall, 1991, Analytical biochemistry.

Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen.

S. Hall, D. Brater, A. C. Rudy, 1991, The Journal of pharmacology and experimental therapeutics.

Effect of cirrhosis and liver transplantation on the gender difference in QT interval.

Lang Li, N. Chalasani, D. Flockhart, 2005, The American journal of cardiology.

Association of genotypes of the CYP3A cluster with midazolam disposition in vivo

M. Radovich, S. Hall, S. Kim, 2012, The Pharmacogenomics Journal.

Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes.

S. Wrighton, A. Rettie, B. Haehner‐Daniels, 2000, Biochemical pharmacology.

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

B. Ring, S. Wrighton, S. Hall, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

Ann Daly, Jatinder Lamba, M. Boguski, 2001, Nature Genetics.

The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity

Shiew-Mei Huang, L. Lesko, J. Gorski, 2001, Clinical pharmacology and therapeutics.

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Andy Z. X. Zhu, Yuan Chen, E. Schuck, 2019, CPT: pharmacometrics & systems pharmacology.

Hydroxyitraconazole, Formed During Intestinal First-Pass Metabolism of Itraconazole, Controls the Time Course of Hepatic CYP3A Inhibition and the Bioavailability of Itraconazole in Rats

R. Kimura, S. Hall, M. Hamman, 2008, Drug Metabolism and Disposition.

Suicidal Ideation Is Associated With HIV Transmission Risk in Men Who Have Sex With Men

L. Szczech, A. Carrico, T. Neilands, 2010, Journal of acquired immune deficiency syndromes.

Effect of St John's wort on the pharmacokinetics of fexofenadine

Shiew-Mei Huang, L. Lesko, Zaiqi Wang, 2002, Clinical pharmacology and therapeutics.

Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies

S. Hall, J. W. Higgins, A. Ke, 2014, Clinical pharmacology and therapeutics.

SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5

Jennifer B Dennison, P. Kulanthaivel, S. Hall, 2006, Drug Metabolism and Disposition.

Physiologically based pharmacokinetic modeling to understand the observed drug–drug interaction of LY2623091 with CYP3A inhibitors itraconazole and diltiazem

M. Posada, S. Hall, G. Dickinson, 2017 .

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2C9 and CYP3A4 Substrates

M. Mohutsky, S. Hall, D. Bedwell, 2017, Drug Metabolism and Disposition.

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2D6 Substrates

M. Mohutsky, S. Hall, D. Bedwell, 2016, Drug Metabolism and Disposition.

Effect of race on vincristine‐associated neurotoxicity in pediatric acute lymphoblastic leukemia patients

S. Hall, K. McCammack, J. Renbarger, 2008, Pediatric blood & cancer.

Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma

Jialin Mao, S. Wrighton, M. Mohutsky, 2011, Drug Metabolism and Disposition.

Inhibition of CYP3A by Erythromycin: In Vitro-In Vivo Correlation in Rats

R. Kimura, S. Hall, S. Quinney, 2010, Drug Metabolism and Disposition.

Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes

Jennifer B Dennison, S. Hall, J. Renbarger, 2007, Journal of Pharmacology and Experimental Therapeutics.

The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition.

S. Hall, R. Galinsky, M. Franklin, 2002, Drug metabolism and disposition: the biological fate of chemicals.

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

S. Wrighton, J. Gorski, S. Hall, 2002, British journal of clinical pharmacology.

Stereoselective disposition of flurbiprofen in normal volunteers.

S. Hall, D. Brater, M. Knadler, 1992, British journal of clinical pharmacology.

Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective

Andy Z. X. Zhu, Yuan Chen, I. Poggesi, 2020, Clinical pharmacology and therapeutics.

Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans.

Lang Li, J. Gorski, Zaiqi Wang, 2003, British journal of clinical pharmacology.

Stereoselective Pharmacokinetics and Inversion of (R)‐ Ketoprofen in Healthy Volunteers

S. Hall, D. Brater, A. C. Rudy, 1998, Journal of clinical pharmacology.

Molecular and physical mechanisms of first-pass extraction.

R. Fontana, P. Watkins, L. Benet, 1999, Drug metabolism and disposition: the biological fate of chemicals.

The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America

Chuang Lu, Heidi J Einolf, Y. Wong, 2009, Drug Metabolism and Disposition.

A simple system for the investigation of protein binding effects on the renal handling of drugs in an isolated perfused rat kidney preparation.

M. Rowland, S. Hall, 1984, Journal of pharmacological methods.

Bimodal distribution of renal cytochrome P450 3A activity in humans.

P. Watkins, S. Wrighton, J. Gorski, 1996, Molecular pharmacology.

Stereoselective high-performance liquid chromatographic analysis of ketoprofen and its acyl glucuronides in chronic renal insufficiency.

S. Hall, D. Rudy, N. Grubb, 1996, Journal of chromatography. B, Biomedical applications.

Relationship between lipophilicity and tubular reabsorption for a series of 5-alkyl-5-ethylbarbituric acids in the isolated perfused rat kidney preparation.

M. Rowland, S. Hall, J. Mayer, 1988, Journal of pharmaceutical sciences.

Effect of 3'-azido-3'-deoxythymidine (AZT) on organic ion transport in rat renal brush border membrane vesicles.

S. Hall, P. Sokol, D. Griffiths, 1992, The Journal of pharmacology and experimental therapeutics.

Interaction of 3'-azido-3'-deoxythymidine with organic ion transport in rat renal basolateral membrane vesicles.

S. Hall, P. Sokol, D. Griffiths, 1991, The Journal of pharmacology and experimental therapeutics.

In vivo effects of interleukin‐10 on human cytochrome P450 activity

J. Gorski, S. Hall, D. Cutler, 2000, Clinical pharmacology and therapeutics.

Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin.

A. Li, J. Gorski, S. Hall, 1997, Chemico-biological interactions.

CHAPTER 98 – Disposition and Dose Requirements of Drugs in Renal Insufficiency

S. Hall, D. Brater, S. Hall, 2008 .

The interaction between St John's wort and an oral contraceptive

Shiew-Mei Huang, J. Gorski, Zaiqi Wang, 2003, Clinical pharmacology and therapeutics.

Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib

Maria M. Posada, Stephen D. Hall, K. Hillgren, 2017, Clinical and translational science.

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.

S. Hall, Ying-Hong Wang, David R. Jones, 2004, Drug metabolism and disposition: the biological fate of chemicals.

PREDICTION OF CYTOCHROME P 450 3 A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES

S. Hall, David R. Jones, Ying-hong Wang, 2004 .

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Joe Kesterson, N. Chalasani, H. Aljadhey, 2004, Gastroenterology.

Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis

N. Chalasani, D. Crabb, J. Gorski, 2003, Hepatology.

Quantification of Vincristine and its Major Metabolite in Human Plasma by High-Performance Liquid Chromatography/Tandem Mass Spectrometry

Jennifer B Dennison, S. Hall, J. Renbarger, 2008, Therapeutic drug monitoring.

Apparent High CYP3A5 Expression Is Required for Significant Metabolism of Vincristine by Human Cryopreserved Hepatocytes

Jennifer B Dennison, S. Wrighton, M. Mohutsky, 2008, Journal of Pharmacology and Experimental Therapeutics.

Effect of CYP 3 A 5 Expression on Vincristine Metabolism with Human Liver Microsomes

Jennifer B Dennison, S. Hall, J. Renbarger, 2007 .

The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine

Jennifer B Dennison, S. Hall, C. Hadden, 2013, Drug Metabolism and Disposition.

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

S D Hall, S. Wrighton, D. Jones, 1994, Biochemical pharmacology.

An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

S D Hall, D. Jones, S. Hall, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.

D. Jones, J. Gorski, S. Hall, 1999, The Journal of pharmacology and experimental therapeutics.

Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer

P. Kulanthaivel, S. Hall, J. Rehmel, 2020, Drug Metabolism and Disposition.

Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin

N. Chalasani, J. Gorski, S. Hall, 2013, European Journal of Clinical Pharmacology.

Interaction between midazolam and clarithromycin in the elderly.

J. Gorski, S. Hall, S. Quinney, 2008, British journal of clinical pharmacology.

The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity

W. Ambrosius, J. Gorski, B. Haehner‐Daniels, 2003, Clinical pharmacology and therapeutics.

Genetically determined polymorphisms in drug oxidation

R. Branch, S. Hall, E. Jacqz, 1986, Hepatology.

The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants.

J. Hudson, M. Boguski, M. Relling, 2001, Pharmacogenetics.

The role of coenzyme A in the biotransformation of 2-arylpropionic acids.

S. Hall, X. Quan, S. Hall, 1994, Chemico-biological interactions.

Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C.

S D Hall, S. Hall, M. Hamman, 1997, Biochemical pharmacology.

Mechanistic understanding of the phase behavior of supersaturated solutions of poorly water‐soluble drugs

M. Mohutsky, M. Posada, S. Hall, 2018, International journal of pharmaceutics.

The Effects on Metabolic Clearance when Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole

S. Friedrich, S. Hall, B. Willis, 2012, Drug Metabolism and Disposition.

Pulmonary inversion of 2-arylpropionic acids: influence of protein binding.

S. Hall, M. Hassanzadeh-Khayyat, M. Knadler, 1992, Chirality.

Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

C. Ernest, S. Hall, David R. Jones, 2005, Journal of Pharmacology and Experimental Therapeutics.

Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily.

S. Wrighton, D. Jones, J. Gorski, 1999, Xenobiotica; the fate of foreign compounds in biological systems.

High-performance liquid chromatographic analysis of the enantiomers of flurbiprofen and its metabolites in plasma and urine.

S. Hall, M. Knadler, S. Hall, 1989, Journal of chromatography.

Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding.

G R Wilkinson, S D Hall, R. Branch, 1988, The Journal of pharmacology and experimental therapeutics.

Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions

S. Wrighton, M. Mohutsky, J. Mao, 2012, Drug Metabolism and Disposition.

Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate

J. Bonventre, P. Kulanthaivel, S. Hall, 2018, Clinical pharmacology and therapeutics.

The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.

S. Hall, D. Brater, A. C. Rudy, 1994, British Journal of Clinical Pharmacology.

Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.

S. Wrighton, B. Burchell, S. Hall, 2000, Pharmacogenetics.

Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.

S. Wrighton, D. Jones, J. Gorski, 1994, Biochemical pharmacology.

A gel‐free MS‐based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes

Jennifer B Dennison, S. Kornbluth, J. Hall, 2008, Proteomics.

Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions

Xu Han, J. Marc Overhage, Lang Li, 2012, PLoS Comput. Biol..

Effects of flurbiprofen on renal function in patients with moderate renal insufficiency.

A. Manatunga, M. Murray, S. Hall, 1992, British journal of clinical pharmacology.

Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone.

S. Wrighton, D. Jones, J. Gorski, 1997, Xenobiotica; the fate of foreign compounds in biological systems.

Stereoselective disposition of flurbiprofen in uraemic patients.

S. Hall, D. Brater, M. Knadler, 1992, British journal of clinical pharmacology.

Autoactivation and activation of the cytochrome P450s.

S. Ekins, S. Binkley, B. Ring, 1998, International journal of clinical pharmacology and therapeutics.

Influence of fraction unbound upon the renal clearance of furosemide in the isolated perfused rat kidney.

M. Rowland, S. Hall, 1985, The Journal of pharmacology and experimental therapeutics.

Quantitative Structure-Activity Relationship Models of Clinical Pharmacokinetics: Clearance and Volume of Distribution

Vijay K. Gombar, Stephen D. Hall, V. Gombar, 2013, J. Chem. Inf. Model..

Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model

Stephen D. Hall, S. Hall, Yingying Guo, 2015, Drug Metabolism and Disposition.

Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.

Adam J Schwarz, Peng Yu, E. Siemers, 2012, Journal of Alzheimer's disease : JAD.

The interaction of diltiazem with lovastatin and pravastatin

S. Hall, David R. Jones, D. Brater, 1998, Clinical pharmacology and therapeutics.

STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE

Jenny Y Chien, S. Wrighton, J. Chien, 2006, Drug Metabolism and Disposition.

Prediction of the Effect of Erythromycin, Diltiazem, and Their Metabolites, Alone and in Combination, on CYP3A4 Inhibition

S. Hall, David R. Jones, Xin Zhang, 2009, Drug Metabolism and Disposition.

Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.

B. Ring, S. Wrighton, S. Strom, 1998, Pharmacogenetics.

PharmGKB Update: II. CYP3A5, Cytochrome P450, Family 3, Subfamily A, Polypeptide 5

E. Cook, M. Boguski, F. Behm, 2004, Pharmacological Reviews.

Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite

Sara K Quinney, J. Gorski, S. Hall, 2009, Drug Metabolism and Disposition.

Lack of presystemic inversion of (R)‐ to (S)‐ibuprofen in humans

S. Hall, D. Brater, A. C. Rudy, 1993, Clinical pharmacology and therapeutics.

Quantitative Prediction of CYP3A4‐ and CYP3A5‐Mediated Drug Interactions

S. Hall, R. Vuppalanchi, G. Dickinson, 2020, Clinical pharmacology and therapeutics.

Rapid ethanol elimination in patients with type I glycogen storage disease is an adaptive change resulting from recurrent hypoglycemia.

H. Greene, S. Hall, A. Hoyumpa, 1986, The Journal of laboratory and clinical medicine.

Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites

S. Grimm, D. Jones, S. Hall, 2002, Xenobiotica; the fate of foreign compounds in biological systems.

Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug

J Snoeys, S D Hall, L Zhang, 2014, Clinical pharmacology and therapeutics.

A new probabilistic rule for drug–dug interaction prediction

Lang Li, Menggang Yu, J. Chien, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Drug–drug interaction prediction: a Bayesian meta‐analysis approach

Menggang Yu, David A Flockhart, Lang Li, 2007, Statistics in medicine.

Variability in the Disposition of Ibuprofen Enantiomers in Osteoarthritis Patients

S. Hall, A. C. Rudy, J. Bradley, 1992, Therapeutic drug monitoring.

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach

L. Aarons, A. Galetin, A. Rostami-Hodjegan, 2015, Pharmaceutical Research.

DMD050732 1329..1338

J. Chien, J. Mao, S. Hall, 2013 .

Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin

Sara K. Quinney, Lang Li, Stephen D. Hall, 2010, Drug Metabolism and Disposition.

Methodes et compositions a base de r-ibuprofene

S. Hall, Q. Xiaotao, 1997 .

Stereoselective arylpropionyl-CoA thioester formation in vitro.

S. Hall, M. Knadler, S. Hall, 1990, Chirality.

Acute and Chronic Effects of Nonsteroidal Antiinflammatory Drugs on Glomerular Filtration Rate in Elderly Patients

M. Murray, S. Hall, D. Brater, 1995, The American journal of the medical sciences.

Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status.

S. Hall, D. Brater, M. Knadler, 1989, The Journal of pharmacology and experimental therapeutics.

Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects

Lang Li, R. Kovacs, S. Hall, 2007, Clinical pharmacology and therapeutics.

Integration of In Vitro Binding Mechanism Into the Semiphysiologically Based Pharmacokinetic Interaction Model Between Ketoconazole and Midazolam

Lang Li, S. Hall, S. Quinney, 2013, CPT: Pharmacometrics & Systems Pharmacology.

DMD 28746 1 Physiologically-Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP 3 A by Clarithromycin

Lang Li, J. Gorski, S. Hall, 2009 .

Drug–Drug Interaction Prediction Assessment

Lang Li, Lang Li, S. Hall, 2009, Journal of biopharmaceutical statistics.

Hepatic OATP-mediated clearance in the Beagle dog: assessing in vitro-in vivo relationships and applying cross species empirical scaling factors to improve prediction of human clearance

K. Hillgren, A. Galetin, J. Houston, 2018 .

Literature mining on pharmacokinetics numerical data: A feasibility study

Lang Li, Luis Mateus Rocha, Zhiping Wang, 2009, J. Biomed. Informatics.

Metabolic inversion of (R)-ibuprofen. Formation of ibuprofenyl-coenzyme A.

T. Tracy, S. Hall, D. P. Wirthwein, 1993, Drug metabolism and disposition: the biological fate of chemicals.